Confo Therapeutics

Executive Summary

Confo Therapeutics is a clinical-stage biotechnology company headquartered in Ghent, Belgium, dedicated to developing novel therapeutics targeting G protein-coupled receptors (GPCRs) for metabolic, endocrine, and pain indications. Founded in 2015, the company leverages a proprietary technology platform that enables the discovery of both small molecules and antibody-based therapies. This platform addresses the historically challenging druggability of GPCRs, allowing Confo to create highly specific and effective candidates. The lead program, a non-opioid treatment for neuropathic pain, is currently in Phase 1 clinical trials, representing a significant potential alternative to current pain management options with fewer addictive liabilities. Additionally, Confo is advancing a pipeline of preclinical programs focused on metabolic and endocrine diseases. As a private company, Confo Therapeutics has attracted interest from investors and partners seeking to capitalize on its innovative GPCR-targeting approach, which holds promise for addressing substantial unmet medical needs in chronic diseases. The company's progress to date positions it for several near-term milestones that could validate its platform and drive value creation.

Upcoming Catalysts (preview)

• Q1 2027Phase 1 Data Readout for Lead Neuropathic Pain Candidate70% success
• H2 2026Potential Partnership or Licensing Deal for GPCR Platform50% success
• Q3 2026IND Filing for Next-Generation Metabolic Program60% success